tbuckley/cabot-search huggingface dataset:
Low-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients—A Study of the Groupe d'Etude des Lymphomes de l'Adulte
Authors: Didier Decaudin, Eric Lepage, Nicole Brousse, Pauline Brice, Jean-Luc Harousseau, Karim Belhadj, Hervé Tilly, Lucienne Michaux, Stéphane Chèze, Bertrand Coiffier, Philippe Solal-Céligny
Journal: Journal of Clinical Oncology (1999)

To identify the prognostic factors that influence overall survival (OS) in patients with stage III-IV follicular lymphomas and evaluate the clinical usefulness and the prognostic value of the International Prognostic Index (IPI).Four hundred eighty-four patients with Ann Arbor stage III-IV follicular lymphomas treated in two phase III trials from 1986 to 1995 were screened for this study. All histologic slides were reviewed by two hematopathologists. The influence of the initial parameters on survival was defined by univariate (log-rank test) and multivariate (Cox model) analyses.The poor prognostic factors for OS (age > 60 years, "B" symptom(s), > or = two extranodal sites, stage IV disease, tumor bulk > 7 cm, at least three nodal sites > 3 cm, liver involvement, serous effusion-compression or orbital/epidural involvement, and erythrocyte sedimentation rate > 30 mm/h) that were significant in univariate analysis were subjected to multivariate analysis. Three factors remained significant: B symptom(s) (risk ratio = 1.80), age greater than 60 years (risk ratio = 1.60), and at least three nodal sites greater than 3 cm (risk ratio = 1.71). When the IPI was applied to these patients, the score was 1, 2, 3, and 4-5 in 49%, 39%, 11%, and 2%, respectively, and it was significant for progression-free survival (P =.002) and OS (P =.0001).Three prognostic factors for poor OS were identified: B symptoms, age greater than 60 years, and at least three nodal sites greater than 3 cm. The IPI was prognostic for OS, but in this population, a very low number of patients belonged to the high-risk groups.
Abstract 11105: In vivo Assessment of Focal Coronary Artery Spasm by Multislice Computed Tomography
Authors: Tsuyoshi Ito, Mitsuyasu Terashima, Mariko Ehara, Soichiro Ebisawa, Yoshihiro Ko, Maoto Habara, Tairo Kurita, Nobuyoshi Tanaka, Kenya Nasu, Masashi Kimura, Tatsuya Ito, Yoshihisa Kinoshita, Etsuo Tsuchikane, Keiko Asakura, Yasushi Asakura, Osamu Kato, Takahiko Suzuki
Journal: Circulation (2010)

Background: Coronary artery spasm has been shown to play an important role in the pathogenesis of not only variant angina but also many types of ischemic heart disease. Previous studies have shown ...
Occupational exposures estimated by a population specific job exposure matrix and 25 year incidence rate of chronic nonspecific lung disease (CNSLD): the Zutphen Study
Authors: WK Post, D Heederik, H Kromhout, D Kromhout
Journal: European Respiratory Journal (1994)

The influence of occupational exposures on total mortality and respiratory mortality and morbidity was examined, employing a population specific Job Exposure Matrix (JEM). Moreover, the relationship between time-related variables of exposure to dust and chronic nonspecific lung disease (CNSLD) incidence was analysed, using time since first exposure and duration of exposure. Occupational exposures in the Zutphen cohort were assessed by application of a JEM, arbitrarily considering jobs as exposed when at least 10% of men who had held the job of interest reported an exposure to one or more from a list of 27 chemical agents. None of the exposures was related to mortality due to CNSLD, although results were influenced by the healthy-worker effect and low mortality rates. Exposure to wood dust and a high probability of exposure to dust were associated with total mortality. Exposures to dust and solvents were statistically significantly related to CNSLD incidence. An exposure-response relationship was found for the probability of exposure to dust with CNSLD incidence. Time-related estimates of exposure to dust based on work history were negatively related to CNSLD incidence. The results suggest the presence of a healthy-worker effect, in a general population study, resulting in an underestimation of the relationship between occupational exposures and respiratory diseases based on the evidence published so far. The use of the full work history to determine exposure to dust leads to stronger relationships with CNSLD incidence, compared to conventional analyses using exposure at the start of follow-up.
Ambulatory blood pressure and respiratory function dynamics under the influence of vasoactive antihypertensive drugs in smokers
Authors: Olga Fedorishina, Konstantin Protasov
Journal: European Respiratory Journal (2013)

Objective. To compare the antihypertensive efficacy of carvedilol, nebivolole and amlodipine in smoking and non-smoking hypertensive patients.

Methods. 130 patients with arterial hypertension aged 30-55 years were randomized to carvedilol (n=56), nebivolol (n=44) and amlodipine (n=30) groups. The groups were divided into smokers and non-smokers (or former smokers >1 year) subgroups. In each subgroup office blood pressure (BP), ambulatory BP monitoring (ABPM) and spirometry parameters were evaluated and compared initially and after 8 weeks of treatment.

Results. Office BP significantly reduced by the same extent in all groups. At once we did not find the BP dynamics in smokers taking carvedilol unlike non-smokers by ABPM data. In smokers taking nebivolol mean 24-h systolic BP also did not decrease, however the BP variability fell. Amlodipine equally well reduced the mean 24-h, daily and nighttime BP both in smokers and non-smokers. Respiratory function did not change in smokers of amlodipine group (FEV1 – 100.9±9.5 % at the baseline and 103.0±8.5 % at the end of the study), while taking of beta-blockers was followed by its deterioration: the FEV1 decreased from 100.1±9.8% to 98.6±10.7% (p<0,05) under the influence of carvedilol and from 100.8±23.5 % to 97.0±22.7 % (p<0,05) during the treatment with nebivolol.

Conclusion. The attenuation of carvedilol and nebivolol antihypertensive efficacy was revealed in young and middle age hypertensive smokers. At the same time the antihypertensive efficacy of amlodipine was high regardless of smoking status.
NAVA and PSV ventilation in neuromuscular and COPD difficult-to-wean patients
Authors: G. Vagheggini, S. Mazzoleni, E. Panait Vlad, S. Tarantino, M.C. Carrozza, N. Ambrosino
Journal: European Respiratory Journal (2013)

Aim of the study is to compare ventilatory parameters and diaphragmatic electromyography (EAdi) during pressure support ventilation (PSV) and neurally adjusted ventilatory assist (NAVA) in difficult to wean patients (DW).  Five chronic obstructive (COPD) (4males, age 69.8±5.7y) and 5 neuromuscular (NMD) (2males, age 72.2±11.1y) DW underwent a sequence of progressive inspiratory support reduction in NAVA and in PSV, from baseline (BL) to the onset of dyspnoea or ventilator discomfort (FL), as assessed by Borg ≥ 6. Tidal volume (VT), minute ventilation (VE), peak EAdi (EAdipeak) and neural inspiratory time (TiNeur), Diaphragmatic effort (IEAdi) were computed from pressure, flow and EAdi signals derived from ventilator.  Compared to COPD, in both ventilation modalities NMD showed at FL higher IEAdi (NAVA: 14.9±22.7 vs 9.7±12.0; PSV: 14.5±10.8 vs 11.2±11.1µV*s) and lower VT/EAdipeak (NAVA: 0.3±0.9 vs 0.9±3.2; PSV: 0.2±0.1 vs 0.7±0.7 ml/kg*µV) (P  NMD showed an higher tolerance threshold compared to COPD. At FL, NMD ventilator pattern was characterized by higher IEAdi and TiNeur in NAVA compared to PSV. In this group, despite of a lower EAdipeak, an higher inspiratory effort effectiveness, as shown by VT/EAdipeak values, was observed in NAVA compared to PSV. These preliminary results require further investigations to confirm possible advantages of NAVA in NMD.
Primary Cutaneous Non-Hodgkin’s Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy
Authors: Andreas H. Sarris, Ira Braunschweig, L. Jeffrey Medeiros, Madeleine Duvic, Chul S. Ha, M. Alma Rodriguez, Frederick B. Hagemeister, Peter McLaughlin, Jorge Romaguera, James Cox, Fernando Cabanillas
Journal: Journal of Clinical Oncology (2001)

PURPOSE: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin’s lymphoma (PCNHL). PATIENTS AND METHODS: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. RESULTS: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95%. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50% of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial ± SE) was 61% ± 7% and survival was 58% ± 9% at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% ± 12% (P = .0003) versus 0% after radiotherapy; survival was 77% ± 12% versus 25% ± 22% (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% ± 11% and survival 70% ± 18%. CONCLUSION: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.
Serodiagnosis of mycobacterium avium-complex pulmonary disease using anti-glycopeptidolipid core antigen IgA antibody
Authors: Yosuke Kamiya, Yusuke Amano, Yoichiro Aoshima, Tomohiro Uto, Shinya Sagisaka, Jun Sato, Shiro Imokawa, Kazumasa Yasuda, Takafumi Suda, Kingo Chida
Journal: European Respiratory Journal (2013)

Rationale: Pulmonary diseases due to non-tuberculous mycobacteria(pNTM) has been increasing in Japan. The diagnosis of Mycobacterium avium-complex pulmonary disease (MAC-PD) is complicated.  Objectives: Our aim of this study was to evaluate a serodiagnosis of MAC-PD using anti-glycopeptidolipid(GPL) core antigen IgA antibody.  Methods and Results: Between April 2012 and December 2012, the levels of serum anti-glycopeptidolipid(GPL) core antigen IgA antibody were measured in 69 patients in our hospital: 53 patients with MAC-PD, 4 with non-MAC pNTM (M.kansasii, M.Scrofulaceum, M.goldonae, M.abscessus), 7 with pulmonary tuberculosis, and 5 with lung cancer. The MAC-PD group included infections with M. avium (n =28), and M. intracellulare (n = 25). The patients of MAC-PD and non-MAC pNTM fulfilled the American Thoracic Society (ATS) criteria for the diagnosis of NTM infection. None of the patients was seropositive for HIV type1 or 2. The level of serum IgA antibody to GPL core antigen was quantified using the ELISA kit. Setting the cutoff point at 0.7 U/ml resulted in 71.7% sensitivity and 93.8% specificity of diagnosing MAC-PD. Of the 4 patients with Non-MAC pNTM group, only one patient with M.abscessus had positive result. All the patients of tuberculosis and lung cancer had negative results for anti-glycopeptidolipid core antigen IgA antibody.  Conclusion: The ELISA kit of serum IgA antibody specific for GPL core antigen is useful for the rapid diagnosis of MAC-PD.
Abstract 2924: MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma
Authors: Jyoti Asundi, Paul Polakis, Jennifer A. Lacap, Michelle Nannini
Journal: Cancer Research (2014)

Abstract Therapies targeting the MAP kinase pathway in melanoma have produced significant clinical responses; however, duration of response is limited by acquisition of drug resistance. Rationale drug combinations may improve outcomes in this setting. We assessed the therapeutic combination of an antibody drug conjugate (ADC) targeting the Endothelin B receptor (EDNRB) with small molecule inhibitors of the MAP kinase signaling pathway in melanoma. Cell lines and tumor models containing either mutant BRAF or NRAS, or wildtype for both, were exposed to small molecule inhibitors or BRAF and MEK. Expression of EDNRB was analyzed and the therapeutic impact of combining the anti-EDNRB ADC with the BRAF and MEK inhibitors was assessed. Increased expression of EDNRB in response to inhibition of BRAF and/or MEK was observed and augmented the antitumor activity of the ADC. Enhanced target expression and ADC anti-tumor activity were realized irrespective of the response of the tumor model to the BRAF or MEK inhibitors alone and could be achieved in melanoma with mutant NRAS, BRAF or neither mutation. Cells that acquired resistance to BRAF inhibition through long-term culture retained drug-induced elevated levels of EDNRB expression. Expression of EDNRB was not enhanced in normal human melanocytes by inhibition of BRAF and the combination of the ADC with MAPK inhibitors was well tolerated in mice. The anti-EDNRB ADC combines well with BRAF and MEK inhibitors and could have therapeutic utility in the majority of human melanoma cases. Citation Format: Jyoti Asundi, Paul Polakis, Jennifer A. Lacap, Michelle Nannini. MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2924. doi:10.1158/1538-7445.AM2014-2924
Misclassification of Acceptable Venous Thromboembolism Prophylaxis Leading to Flawed Inferences and Recommendations Regarding Prevention Efforts
Authors: Victor O. Popoola, Brandyn D. Lau, Elliott R. Haut
Journal: JAMA Surgery (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Patient Preferences Versus Physician Perceptions of Treatment Decisions in Cancer Care
Authors: Eduardo Bruera, Catherine Sweeney, Kathryn Calder, Lynn Palmer, Suzanne Benisch-Tolley
Journal: Journal of Clinical Oncology (2001)

PURPOSE: To examine patient preferences as well as physician perceptions of these preferences for decision making and communication in palliative care. PATIENTS AND METHODS: Medical decision-making preferences (DMPs) were prospectively studied in 78 assessable cancer patients after initial assessment at a palliative care outpatient clinic. DMPs were assessed with a questionnaire using five possible choices ranging from 1 (patient prefers to make the treatment decision) to 5 (patient prefers the physician to make the decision). In addition, the physician’s perception of this preference was assessed. RESULTS: Full concordance between the physician and the patient was seen in 30 (38%) of 78 cases; when the five original categories were recombined to cover active, shared, and passive decision making, there was concordance in 35 (45%) of 78 cases. The kappa coefficient for agreement between physician and patient was poor at 0.14 (95% confidence limit, −0.01 to 0.30) for simple kappa and 0.17 (95% confidence interval [CI], 0.00 to 0.34) for weighted kappa (calculated on the three regrouped categories). Active, shared, and passive DMPs were chosen by 16 (20%) of 78, 49 (63%) of 78, and 13 (17%) of 78 patients, and by 23 (29%) of 78, 30 (39%) of 78, and 25 (32%) of 78 physicians, respectively. The majority of patients (49 [63%] of 78; 95% CI, 0.51 to 0.74) preferred a shared approach with physicians. Physicians predicted that patients preferred a less shared approach than they in fact did. Patient age or sex did not significantly alter DMP. CONCLUSION: An individual approach is needed and each patient should be assessed prospectively for DMP.
Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis
Authors: Kenneth R. Chapman, Ekkehard Beck, Daniel Alcaide, Esther Garcia Gil
Journal: European Respiratory Journal (2014)

Background   There has been recent controversy regarding the safety, particularly cardiovascular (CV) safety, of tiotropium, an inhaled anticholinergic, in the treatment of chronic obstructive pulmonary disease (COPD).   Aim   To evaluate the safety of another anticholinergic, aclidinium bromide 400 µg twice daily (BID), in patients with COPD.   Methods   Safety data have been pooled from the placebo and aclidinium 400 µg BID arms of six, Phase III, placebo-controlled, parallel-group studies (≥1 month to 1 year duration) evaluating both aclidinium mono- and combination therapy.   Results   A total of 2781 patients with moderate-to-severe COPD were included. The overall safety profile of aclidinium 400 µg BID was similar to that of placebo (Table). There was no difference between aclidinium and placebo in terms of overall CV safety, including major adverse CV events (MACE: composite of CV death, non-fatal myocardial infarction and non-fatal stroke; Table) and any cerebrovascular event. Moreover, the incidence of cardiac and cerebrovascular events was similar for patients with CV risk factors versus placebo (RR=1.06, 95% CI=0.77, 1.46). The incidence of anticholinergic adverse events with aclidinium was low (   Conclusions   Aclidinium has a good safety profile with no evidence of increased CV or cerebrovascular risk compared with placebo.
Carcinogenic Activity of &lt;italic&gt;Symphytum officinale&lt;/italic&gt;&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Iwao Hirono, Hideki Mori, Masanobu Haga
Journal: JNCI Journal of the National Cancer Institute (1978)

The carcinogenicity of Symphytum officinale L., Russian comfrey, used as a green vegetable or tonic, was studied in inbred ACI rats. Three groups of 19--28 rats each were fed comfrey leaves for 480--600 days; four additional groups of 15--24 rats were fed comfrey roots for varying lengths of time. A control group was given a normal diet. Hepatocellular adenomas were induced in all experimental groups that received the diets containing comfrey roots and leaves. Hemangioendothelial sarcoma of the liver was infrequently induced.
Relationship Between the Cellular and Viral Antigens of a BALB/c Myeloma and Murine Leukemia Virus2
Authors: Robert G. Krueger, Gerald C. Miller
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Relationship Between the Cellular and Viral Antigens of a BALB/c Myeloma and Murine Leukemia Virus Get access Robert G. Krueger, Robert G. Krueger 3Department of Microbiology, Mayo Medical School, Mayo Foundation, Rochester, Minn. 55901. Search for other works by this author on: Oxford Academic PubMed Google Scholar Gerald C. Miller Gerald C. Miller 3Department of Microbiology, Mayo Medical School, Mayo Foundation, Rochester, Minn. 55901. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 4, October 1974, Pages 997–1004, https://doi.org/10.1093/jnci/53.4.997 Published: 01 October 1974 Article history Received: 31 January 1974 Accepted: 18 June 1974 Published: 01 October 1974
Changes in serotypes causing invasive pneumococcal disease (2005–2007 vs. 1997–1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine
Authors: L. Salleras, A. Domínguez, P. Ciruela, C. Izquierdo, E. Navas, N. Torner, E. Borras
Journal: Clinical Microbiology and Infection (2009)
Pharmacodynamic (PD) endpoints and cellular proliferation effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in breast cancer cells and xenografts with wild-type (WT) and activating PI3K mutations
Authors: B. Markman, V. Serra, M. Scaltriti, V. Valero, M. Guzman, C. Garcia-Echevarria, M. Maira, J. Baselga
Journal: Journal of Clinical Oncology (2008)

14508 Background: PI3K mutations are frequent in human cancer and play a role in the malignant phenotype and therapeutic resistance. NVP-BEZ235 is a small molecular mass compound in phase I clinical studies. NVP-BEZ235 reversibly blocks the ATP binding pocket on both the p110 catalytic subunit of PI3Ks and mTOR. Our aims were to study the activity and PD markers of NVP-BEZ235 in breast cancer cell lines with activating PI3K mutations. Methods: A panel of breast cancer cell lines with either WT, endogenous PI3K activating mutations or over- expressing oncogenic p110α mutants were treated with NVP-BEZ235. A xenograft breast cancer model was used to determine in vivo effects. Results: Target inhibition by NVP-BEZ235 was achieved as evidenced by a reduction in the level of the phosphorylated form of Akt, S6 and 4EBP-1, plus the nuclear re-localisation of FoxO3a. Cellular proliferation in all tested cancer cell lines was strongly inhibited in the nanomolar range as determined by the growth inhibitory 50 concentration values. NVP-BEZ235 induced G1 cell cycle arrest and apoptosis in the breast cancer cell lines tested as determined by fluorescence-activated cell sorting and the presence of cleaved PARP. There was a strong correlation between the concentrations that inhibited signalling and those that induced a growth inhibitory effect. Importantly, NVP-BEZ235 was significantly active in cell cultures harbouring oncogenic PI3K mutants and demonstrated activity in models of trastuzumab resistance. Statistically significant antitumor activity was observed upon oral administration of NVP-BEZ235 to mice bearing breast cancer xenografts at tolerated doses. PD endpoints (p-Akt, p-4EBP1 and p-S6) in tumour tissue were reduced after compound treatment. Conclusions: NVP- BEZ235 shows a rapid and profound inhibition of the PI3K pathway and results in tumor cell growth inhibition and apoptosis. Disease stasis and inhibition of PD biomarkers was observed in breast cancer xenograft models. The observed correlation between the in vivo antitumor activity and the selected PD endpoints suggests that these markers may be of assistance in the dose-finding studies in patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Pharma AG Novartis Pharma AG